Doxorubicin layer-by-layer nanoparticles for controlled delivery and effective treatment of pancreatic cancer
Abstract
Introduction: Layer-by-layer (LbL) nanoparticles consist of a versatile drug delivery technique, for targeted and controlled delivery. The Doxorubicin (DRC) is being widely used for treatment of pancreatic cancer (PCR). The present study was performed to develop and evaluation LbL nanoparticles (NP’s) of DRC to provide controlled and targeted delivery for effective treatment of PCR.
Materials and Method: A liposomal based polymeric pH sensitive NP’s were prepared by utilizing LbL techniques. The NP’s were composed lipids, poly (b-amino ester) (PAE) and hyaluronic acid (HAC). The physiochemical properties of DRC-LbL NPs was evaluated such as particle size, zeta potential, percent entrapment efficiency (%EE), loading of drug and In-vitro drug release behavior. The surface morphology of LbL NP’s was evaluated by scanning electronic microscopy (SEM). The in vitro release of DRC-LbL-NP’s was determined by using Dialysis technique at pH 5 and 7.
Results: Results showed that developed DRC-LbL NP’s having average particle size of 182.94 + 4.11 nm, zeta potential (ZP) of -42.78± 3.2mV, higher drug entrapment efficiency (EE) of 74.94±3.45. The in-vitro drug release from DRC-LbL NP’s exhibited sustained release pattern and it was triggered by lower pH. The surface morphology of developed DRC-LbL NP’s exhibited smooth and uniform particle size in nano range. The results from in-vitro drug release showed that there was significant difference in amount of DRC release in both pH media. In phosphate buffer pH 7.4 the total amount of DRC release was found to be 44.82 % after 48 hour of study whereas in pH 5.0 it was recorded 98.24% after 48 hours.
Conclusion: The results from present study conclude that DRC-LbL NPs might be a promising candidate for the effective treatment of pancreatic cancer.
Keywords: Layer-by-layer, Nanoparticles, Doxorubicin, Controlled delivery, Targeted Delivery
Keywords:
Layer-by-layer, Nanoparticles, Doxorubicin, Controlled delivery, Targeted DeliveryDOI
https://doi.org/10.22270/jddt.v13i6.5829References
Galluzzi L, Buque A, Kepp O, et al. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015; 28(6):690-714. https://doi.org/10.1016/j.ccell.2015.10.012
Zhang CY, Yang YQ, Huang TX, et al. Self-assembled pH-responsive MPEG-b-(PLA-co-PAE) block copolymer micelles for anticancer drug delivery. Biomaterials 2012; 33(26):6273-83. https://doi.org/10.1016/j.biomaterials.2012.05.025
Yang J, Lv Q, Wei W, et al. Bioresponsive albumin-conjugated paclitaxel prodrugs for cancer therapy. Drug Deliv 2018; 25(1):807-14. https://doi.org/10.1080/10717544.2018.1451935
Venditto VJ, Simanek EE. Cancer therapies utilizing the camptothecins: a review of the in vivo literature. Mol Pharm 2010; 7(2):307-49. https://doi.org/10.1021/mp900243b
Jungk C, Chatziaslanidou D, Ahmadi R, et al. Chemotherapy with BCNU in recurrent glioma: analysis of clinical outcome and side effects in chemotherapy-naïve patients. BMC Cancer 2016; 16 (1):81. https://doi.org/10.1186/s12885-016-2131-6
Bolhuis H, Veen HW, Poolman B, Driessen AJM, Konings WN. Mechanism of multidrug transporters. FEMS Microbiol Rev 1997; 21(1): 55-84. https://doi.org/10.1111/j.1574-6976.1997.tb00345.x
Chen D, Yu H, Sun K, et al. Dual thermoresponsive and pHresponsive self-assembled micellar nanogel for anticancer drug delivery. Drug Deliv 2014; 21 (4):258-64. https://doi.org/10.3109/10717544.2013.838717
Zhang CY, Chen Q, Wu WS, et al. Synthesis and evaluation of cholesterol-grafted PEGylated peptides with pH-triggered property as novel drug carriers for cancer chemotherapy. Colloids Surf B Biointerfaces 2016; 142:55-64. https://doi.org/10.1016/j.colsurfb.2016.02.025
Dong H, Pang L, Cong H, et al. Application and design of esterase responsive nanoparticles for cancer therapy. Drug Deliv 2019; 26 (1):416-32. https://doi.org/10.1080/10717544.2019.1588424
Wang Y, Zhang H, Hao J, et al. Lung cancer combination therapy: co-delivery of paclitaxel and doxorubicin by nanostructured lipid carriers for synergistic effect. Drug Deliv 2016; 23(4):1398-403. https://doi.org/10.3109/10717544.2015.1055619
Alotaibi HF, Perni S, Prokopovich P. Nanoparticle-based model of anti-inflammatory drug releasing LbL coatings for uncemented prosthesis aseptic loosening prevention. Int J Nanomedicine 2019; 14:7309-22. https://doi.org/10.2147/IJN.S217112
Xie L, Tong W, Yu D, et al. Bovine serum albumin nanoparticles modified with multilayers and aptamers for pH-responsive and targeted anti-cancer drug delivery. J Mater Chem 2012; 22(13):6053-60. https://doi.org/10.1039/c2jm16831f
Raza F, Zhu Y, Chen L, et al. Paclitaxel-loaded pH responsive hydrogel based on self-assembled peptides for tumor targeting. Biomater Sci 2019; 7(5):2023-36. https://doi.org/10.1039/C9BM00139E
Wojtkowiak JW, Verduzco D, Schramm KJ, Gillies RJ. Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol Pharm 2011; 8(6):2032-8. https://doi.org/10.1021/mp200292c
Huang X, Liao W, Zhang G, et al. pH-sensitive micelles selfassembled from polymer brush (PAE-g-cholesterol)-b-PEG-b-(PAE-gcholesterol) for anticancer drug delivery and controlled release. Int J Nanomedicine 2017; 12:2215-26. https://doi.org/10.2147/IJN.S130037
Limeres MJ, Moretton MA, Bernabeu E, et al. Thinking small, doing big: current success and future trends in drug delivery systems for improving cancer therapy with special focus on liver cancer. Mater Sci Eng C Mater Biol Appl 2019; 95:328-41. https://doi.org/10.1016/j.msec.2018.11.001
Pham PV, Phan NL, Nguyen NT, et al. Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy. J Transl Med 2011; 9:209. https://doi.org/10.1186/1479-5876-9-209
Misra S, Hascall VC, Markwald RR, Ghatak S. Interactions between hyaluronan and its receptors (CD44, RHAMM) regulate the activities of inflammation and cancer. Front Immunol 2015; 6:201. https://doi.org/10.3389/fimmu.2015.00201
Li X, Hirsh DJ, Cabral-Lilly D, et al. Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient. Biochim Biophys Acta 1998; 1415:23-40. https://doi.org/10.1016/S0005-2736(98)00175-8
Poon Z, Chang D, Zhao X, Hammond PT. Layer-by-layer nanoparticles with a pH-sheddable layer for in vivo targeting of tumor hypoxia. ACS Nano 2011; 5 (6):4284-92. https://doi.org/10.1021/nn200876f
Men W, Zhu P, Dong S et. al. Layer-by-layer pH-sensitive nanoparticles for drug delivery and controlled release with improved therapeutic efficacy in vivo. Drug Del. 2020; 27(1):180-190
https://doi.org/10.1080/10717544.2019.1709922
Khalil RM, Abd-Elbary A, Kassem MA, et al. (2014). Nanostructured lipid carriers (NLCs) versus solid lipid nanoparticles (SLNs) for topical delivery of meloxicam. Pharm Dev Technol 2014; 19(4):304-14. https://doi.org/10.3109/10837450.2013.778872
ICH guidelines for stability testing for new drug substances and products (ICH Q1A). https://www.ich.org/page/quality-guidelines. [Assessed on 08 Sept. 2021]
Pubchem Doxrobucin. https://pubchem.ncbi.nlm.nih.gov/compound/31703#section=Computed-Properties. [Assessed on 08 Sept. 2021]
Negi JS, Chattopadhyay P, Sharma AK, Ram V. Development of solid lipid nanoparticles (SLNs) of lopinavir using hot self nano-emulsification (SNE) technique. Eur J Pharm Sci 2013; 48(1-2):231-9. https://doi.org/10.1016/j.ejps.2012.10.022
Gondrala UK, Dudhipala N, Kishan V. Preparation, characterization and in vivo evaluation of felodipine solid-lipid nanoparticles for improved oral bioavailability. Int J Pharm Sci Nanotech. 2015; 8(4):2995-3002. https://doi.org/10.37285/ijpsn.2015.8.4.1
Shen Y, Tang H, Zhan Y, et al. Degradable poly(b-amino ester) nanoparticles for cancer cytoplasmic drug delivery. Nanomedicine 2009; 5(2): 192-201. https://doi.org/10.1016/j.nano.2008.09.003
Niu S, Bremner DH, Wu J, et al. L-Peptide functionalized dualresponsive nanoparticles for controlled paclitaxel release and enhanced apoptosis in breast cancer cells. Drug Deliv 2018; 25(1):1275-88. https://doi.org/10.1080/10717544.2018.1477863
Published
Abstract Display: 543 
PDF Downloads: 647 PDF Downloads: 41 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.